Related Experiment Video
Updated: Jun 3, 2026
12:28
Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
Published on: June 3, 2020
[Brain SPECT in Lewy body dementia]
Karim Farid1, Lisette Volpe-Gillot, Nadine Caillat-Vigneron
1AP-HP, hôpital Hôtel-Dieu de Paris, service de médecine nucléaire, 75004 Paris, France. kwfarid@hotmail.com
Presse Medicale (Paris, France : 1983)
|March 8, 2011
Summary
Dementia with Lewy bodies (DLB) diagnosis is aided by brain SPECT scans showing reduced blood flow in posterior brain regions and dopamine system deficits. These findings help differentiate DLB from other dementias.
Area of Science:
- Neurology
- Nuclear Medicine
Background:
- Dementia with Lewy bodies (DLB) is the second most common cause of degenerative dementia.
- DLB presents with diverse clinical manifestations, complicating diagnosis.
- Cerebral blood flow assessment using brain single photon computed tomography (SPECT) is a routine diagnostic tool.
Purpose of the Study:
- To evaluate the utility of brain SPECT in the differential diagnosis of dementia with Lewy bodies.
- To characterize the neuroimaging findings associated with DLB using perfusion and neurotransmission SPECT.
Main Methods:
- Cerebral perfusion SPECT was used to assess regional cerebral blood flow.
- Cerebral neurotransmission SPECT (DaTSCAN®) was employed to evaluate dopaminergic integrity.
- SPECT findings in DLB patients were analyzed for characteristic patterns.
Main Results:
- Cerebral perfusion SPECT revealed diffuse cortical hypoperfusion in DLB, predominantly in posterior regions, affecting visual areas.
- DLB patients exhibited striatal hypofixation on DaTSCAN®, indicating dopaminergic system dysfunction.
- SPECT imaging demonstrated distinct patterns differentiating DLB from other dementia types.
Conclusions:
- Brain SPECT, encompassing both perfusion and neurotransmission imaging, is a valuable tool for diagnosing dementia with Lewy bodies.
- SPECT findings correlate with the underlying neurobiology of DLB, including hypoperfusion and dopaminergic loss.
- Utilizing SPECT aids in the clinical differentiation of DLB from other neurodegenerative dementias.
Related Concept Videos
01:37Neural Regulation
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.